Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Growth in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 470,700 shares, a growth of 17.5% from the November 15th total of 400,700 shares. Based on an average daily volume of 159,400 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.9% of the company’s shares are sold short.

Immix Biopharma Trading Up 2.9 %

NASDAQ:IMMX traded up $0.06 during trading hours on Monday, hitting $2.10. 61,777 shares of the stock traded hands, compared to its average volume of 184,109. The firm has a 50 day moving average price of $1.78 and a 200 day moving average price of $1.93. The firm has a market cap of $57.77 million, a price-to-earnings ratio of -2.40 and a beta of 0.28. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). Research analysts predict that Immix Biopharma will post -0.64 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Hedge Funds Weigh In On Immix Biopharma

A hedge fund recently raised its stake in Immix Biopharma stock. Geode Capital Management LLC raised its position in Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,082 shares of the company’s stock after purchasing an additional 7,954 shares during the quarter. Geode Capital Management LLC owned approximately 0.55% of Immix Biopharma worth $224,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.